TY - JOUR
T1 - Resting-state global functional connectivity as a biomarker of cognitive reserve in mild cognitive impairment
AU - Franzmeier, Nicolai
AU - Araque Caballero, Miguel A.
AU - Taylor, A. N. W.
AU - Simon-Vermot, Lee
AU - Beurger, Katharina
AU - Ertl-Wagner, Birgit
AU - Mueller, Claudia
AU - Catak, Cihan
AU - Janowitz, Daniel
AU - Baykara, Ebru
AU - Gesierich, Benno
AU - Duering, Marco
AU - Ewers, Michael
N1 - Funding Information:
The research was funded by grants of the LMUexcellent Initiative and the European Commission (ERC, PCIG12-GA-2012-334259), Alzheimer’s Forschung Initiative (AFI, DE-15035). Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ( www.fnih.org ). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.
Publisher Copyright:
© 2016, Springer Science+Business Media New York.
PY - 2017/4/1
Y1 - 2017/4/1
N2 - Cognitive reserve (CR) shows protective effects in Alzheimer’s disease (AD) and reduces the risk of dementia. Despite the clinical significance of CR, a clinically useful diagnostic biomarker of brain changes underlying CR in AD is not available yet. Our aim was to develop a fully-automated approach applied to fMRI to produce a biomarker associated with CR in subjects at increased risk of AD. We computed resting-state global functional connectivity (GFC), i.e. the average connectivity strength, for each voxel within the cognitive control network, which may sustain CR due to its central role in higher cognitive function. In a training sample including 43 mild cognitive impairment (MCI) subjects and 24 healthy controls (HC), we found that MCI subjects with highCR (> median of years of education, CR+) showed increased frequency of high GFC values compared to MCI-CR- and HC. A summary index capturing such a surplus frequency of high GFC was computed (called GFC reserve (GFC-R) index).GFC-R discriminated MCI-CR+ vs. MCI-CR-, with the area under the ROC = 0.84. Cross-validation in an independently recruited test sample of 23 MCI subjects showed that higher levels of the GFC-R index predicted higher years of education and an alternative questionnaire-based proxy of CR, controlled for memory performance, gray matter of the cognitive control network, white matter hyperintensities, age, and gender. In conclusion, the GFC-R index that capturesGFC changes within the cognitive control network provides a biomarker candidate of functional brain changes of CR in patients at increased risk of AD.
AB - Cognitive reserve (CR) shows protective effects in Alzheimer’s disease (AD) and reduces the risk of dementia. Despite the clinical significance of CR, a clinically useful diagnostic biomarker of brain changes underlying CR in AD is not available yet. Our aim was to develop a fully-automated approach applied to fMRI to produce a biomarker associated with CR in subjects at increased risk of AD. We computed resting-state global functional connectivity (GFC), i.e. the average connectivity strength, for each voxel within the cognitive control network, which may sustain CR due to its central role in higher cognitive function. In a training sample including 43 mild cognitive impairment (MCI) subjects and 24 healthy controls (HC), we found that MCI subjects with highCR (> median of years of education, CR+) showed increased frequency of high GFC values compared to MCI-CR- and HC. A summary index capturing such a surplus frequency of high GFC was computed (called GFC reserve (GFC-R) index).GFC-R discriminated MCI-CR+ vs. MCI-CR-, with the area under the ROC = 0.84. Cross-validation in an independently recruited test sample of 23 MCI subjects showed that higher levels of the GFC-R index predicted higher years of education and an alternative questionnaire-based proxy of CR, controlled for memory performance, gray matter of the cognitive control network, white matter hyperintensities, age, and gender. In conclusion, the GFC-R index that capturesGFC changes within the cognitive control network provides a biomarker candidate of functional brain changes of CR in patients at increased risk of AD.
KW - cognitive reserve
KW - biomarker
KW - mild cognitive impairment
KW - Alzheimer's disease
KW - global functional connectivity
KW - resting-state fMRI
KW - Cognitive reserve
KW - Biomarker
KW - Global functional connectivity
KW - Alzheimer’s disease
KW - Mild cognitive impairment
KW - Resting-state fMRI
KW - Humans
KW - Magnetic Resonance Imaging/methods
KW - Male
KW - Reference Values
KW - Connectome/methods
KW - Rest
KW - Sensitivity and Specificity
KW - Cognitive Reserve
KW - Female
KW - Image Interpretation, Computer-Assisted/methods
KW - Neural Pathways/physiopathology
KW - Reproducibility of Results
KW - Brain Mapping/methods
KW - Nerve Net/physiopathology
KW - Biomarkers
KW - Aged
KW - Cerebral Cortex/physiopathology
KW - Cognitive Dysfunction/diagnostic imaging
UR - https://link.springer.com/article/10.1007%2Fs11682-016-9599-1#Sec26
UR - http://www.scopus.com/inward/record.url?scp=84990848472&partnerID=8YFLogxK
U2 - 10.1007/s11682-016-9599-1
DO - 10.1007/s11682-016-9599-1
M3 - Article
C2 - 27709513
SN - 1931-7557
VL - 11
SP - 368
EP - 382
JO - Brain Imaging and Behavior
JF - Brain Imaging and Behavior
IS - 2
ER -